CompletedNot Applicable

OPAL: "Opiates and PhArmacoLogy"

France263 participantsStarted 2013-07-11

Plain-language summary

The aim of this study is to determine the current prevalence of co-addictions, including problem/pathological gambling, in patients receiving Opiate Substitution Treatment (OST), and to then compare patients receiving OST with or without a co-addiction (excluding tobacco dependence) in order to determine their clinical profile. In addition, an ancillary study to be carried out only among those patients receiving methadone, will aim to etablish whether a low plasma concentration of methadone, on the one hand, and an ultrarapid metabolizer genetic profile, on the other, are the characteristics most commonly associated with the presence of co-addictions. This will allow us to complete patient's pharmacological characterization.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

General Inclusion Criteria: * Over 18, * Under treatment unsing methadone or buprenorhine (+/- naloxone) or morphine as substitute, prescribed for opiate dependence, * OST begining at least 6 months previously, * Incarceration for less than a month in the event of monitoring in SMPR, * Good understanding of French, able to read and write. General non-Inclusion Criteria: * Protected adults (guardianship, wardship) * Disorder of higher-order brains functions (severe cognitive disorders or confusion) or psychotic disorder (hallucinations, delusion) that may interfere with the study. Non-Inclusion criteria for patients participating in the ancillary study: * Medical monitoring by a doctor from the Drug Addiction Network of the Nantes Area, * OST other than methadone * Adjustement to dosage in the 5 days prior to administering OST * Pregnant women * Absence of social security registration.

What they're measuring

Presence or absence of co-addictions (exept tobacco dependence)

Timeframe: 1 day

Trial details

NCT IDNCT01847729

SponsorNantes University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-07-21